

Time	講師	司会	ASCO演題		
9:00	開場		ID	Abstract Title	Author
10:00-10:10	Welcome & Introduction 岡本 勇 九州大学病院				
10:10-10:40	泌尿器がん - Prostate Cancer 松原 伸晃 国立がん研究センター東病院	田畑 健一 北里大学病院	5001	Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476).	Nicholas David James
			LBA5002	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).	Howard M. Sandler
			5006	Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.	Christian Carrie
10:40-10:50	Discussion: Q&A				
10:50-11:10	泌尿器がん - Nonprostate Cancer 三浦 裕司 虎の門病院	清水 俊雄 近畿大学	4501*	A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).	Daniel Peter Petrylak
			4506	Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)	Robert Motzer
11:10-11:20	Discussion: Q&A				
11:20-12:00	Patient and Survivor Care 佐々木 治一郎 北里大学病院	朴 成和 国立がん研究センター中央病院	LBA2	Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).	Gregory Armstrong
			9500	Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2).	Jennifer S. Temel
			9501	CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.	Andrew Louis Himelstein
			LBA4	NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.	Paul D. Brown
12:00-12:15	Discussion: Q&A				
12:15-12:30	Break				
12:30-13:30	[ランチョンセミナー] 高張 大亮 がん研有明病院	島田 安博 高知医療センター	胃癌治療におけるラムシルマブの臨床的位置付け 日本イーライリリー株式会社		
13:30-13:45	Break				
13:45-14:15	血液がん - Lymphoma and Plasma cell disorders 丸山 大 国立がん研究センター中央病院	石塚 賢治 福岡大学病院	LBA8502	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.	Laurie Helen Sehn
			8508	ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).	Sagar Lonial
			8509*	Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.	Meletios A. Dimopoulos
14:15-14:25	Discussion: Q&A				
14:25–15:05	血液がん - Leukemia, Myelodysplasia, and Transplantation 南 陽介 神戸大学	照井 康仁 がん研有明病院	7003	Results of a first in human, phase 1/2 trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory(R/R) acute myeloid leukemia (AML).	Mark J. Levis
			LBA7006	Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).	Ruben A. Mesa
			7010	Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL.	Jae Hong Park
			8516	Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas.	Stephen J. Schuster
15:05-15:20	Discussion: Q&A				
15:20-15:35	Coffee Break 15分				
15:35-16:15	肺がん - Immunotherapy 加藤 晃史 神奈川県立循環器呼吸器病センター	笠原 寿郎 金沢大学附属病院	LBA109	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).	Luis Paz-Ares
			8009*	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).	David R. Spigel
			7502	Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.	Patrick Alexander Ott
			7503	Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.	Scott Joseph Antonia
16:15-16:30	Discussion: Q&A				
16:30-17:00	肺がん - Cytotoxic / Molecular - target 岡本 勇 九州大学病院	村上 晴泰 静岡県立静岡がんセンター	8000*	AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.	Suresh S. Ramalingam
			8001	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).	Lecia V. Sequist
			8004*	Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.	Takehito Shukuya
17:00-17:10	Discussion: Q&A				
17:10-17:25	Break 15分				
17:25-18:10	[イブニングセミナー] 山中 竹春 横浜市立大学大学院医学研究科	兵頭 一之介 筑波大学大学院	試験デザインから理解するASCO 2015臨床試験の見方・考え方 中外製薬株式会社		

7月5日（日曜日）

Time	講師	司会	ASCO演題		
7:30	開場		ID	Abstract Title	Author
8:00-8:45	[モーニングセミナー] 高橋 俊二 がん研有明	田村 研治 国立がん研究センター中央病院	甲状腺癌に対する分子標的治療 ～レンパチニブについて エーザイ株式会社		
8:45-9:00	Break 15分				
9:00-9:40	消化器がん - Colorectal Cancer 中島 貴子 聖マリアンナ医科大学	馬場 英司 九州大学	LBA100*	PD-1 blockade in tumors with mismatch repair deficiency.	Dung T. Le
			3501	Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).	Theo Ruers
			3502	SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).	Peter Gibbs
			3512*	Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC):Results of Japan Clinical Oncology Group study (JCOG0910).	Tetsuya Hamaguchi
9:40-9:55	Discussion: Q&A				
9:55-10:25	消化器がん - Noncolorectal Cancer 廣中 秀一 千葉県がんセンター	上野 秀樹 国立がん研究センター中央病院	4000	Phase 3, randomized, double-blind, multicenter, placebo(P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/G EJ) cancer: RILOMET-1 study.	David Cunningham
			4001	Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.	Yung-Jue Bang
			4005	Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).	Matthew H. Kulke
10:25-10:35	Discussion: Q&A				
10:35-11:05	婦人科がん 松本 光史 兵庫県立がんセンター	温泉川 真由 国立がん研究センター中央病院	5500	A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.	Carol Aghajanian
			5508	Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.	Iain A. McNeish
			5509	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial.	Mary L. Disis
11:05-11:15	Discussion: Q&A				
11:15-11:55	頭頸部がん 横田 知哉 静岡県立静岡がんセンター	清田 尚臣 神戸大学	LBA3	Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A Randomised control trial (RCT).	Anil D'Cruz
			6000	Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial.	Lillian L. Siu
			LBA6008	Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.	Tanguy Y. Seiwert
			3011	Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.	Neil Howard Segal
11:55-12:10	Discussion: Q&A				
12:10-12:25	Break 15分				
12:25-13:25	[ランチョンセミナー] 松本 光史 兵庫県立がんセンター	畠 清彦 がん研究会有明病院	持続型G-CSF製剤による発熱性好中球減少症のマネジメント 協和発酵キリン株式会社		
13:25-13:40	Coffee Break 15分				
13:40-14:00	Melanoma/Skin Cancers 山崎 直也 国立がん研究センター中央病院	土井 俊彦 国立がん研究センター東病院	LBA1	Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).	Jedd D. Wolchok
			102	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.	Georgina V. Long
14:00-14:10	Discussion: Q&A				
14:10-14:40	乳がん - ER / HER2 鶴谷 純司 近畿大学	高野 利実 虎の門病院	LBA502	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.	Nicholas C. Turner
			507	Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.	Paul Anthony Ellis
			508	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).	Arlene Chan
14:40-14:50	Discussion: Q&A				
14:50-15:20	乳がん - Triple Negative / Local Therapy 原 文堅 四国がんセンター	田村 研治 国立がん研究センター中央病院	LBA500	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.	Richard G. Margolese
			1006	The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.	Yasuaki Sagara
			1008	Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.	David Krug
15:20-15:30	Discussion: Q&A				
15:30-15:40	Closing Remarks 山本 信之 和歌山県立医科大学				